TREATMENT WITH NOVEL ANTIBODIES
R.H. Advani, Stanford, CA (USA), et al.
Authors Conclusion from the abstract: 5F9+rituximab is a novel immunotherapy blocking a key macrophage/cancer checkpoint. It is well tolerated with rapid and durable responses observed in heavily pre‐treated DLBCL and indolent lymphoma patients. Ph2 enrollment is ongoing (NCT02953509). Funded by Forty Seven and the Leukemia and Lymphoma Society.
M.S. Topp, Würzburg (Germany), et al.
Authors Conclusion from the abstract: R1979 was well tolerated in pts w/ R/R B‐NHL. No DLTs and no significant neurological toxicity were observed. Tx w/ R1979 showed impressive efficacy w/ 100% ORR in R/R FL starting at doses ≥5 mg. More resistant tumors such as R/R DLBCL are showing benefit w/ increasing doses. Based on these efficacy findings, a Phase 2 study in R/R FL Gr 1‐3a, R/R DLBCL, and other R/R B‐NHL subtypes is planned.
Dickinson, Melbourne (Australia), et al.
Authors Conclusion from the abstract: CD20‐TCB is a novel 2:1 format T‐cell‐engaging bispecific antibody which displays highly promising clinical activity in heavily‐pretreated NHL.
J. Radford, Manchester (UK), et al.
Authors Conclusion from the abstract: Lonca at ≥120 μg/kg has substantial antitumor activity in patients with R/R DLBCL. In subgroup analyses, older pts and those with transformed or primary refractory disease had particularly encouraging responses.
G. Collins, Oxford (UK), et al.
Authors Conclusion from the abstract: A difference in Cami response was seen between relapsed vs refractory pts in PK modeling, but response rates were high across all subgroups, suggesting robust antitumor activity across the R/R cHL population. There was a trend for increased ORR in pts with recent prior CHPi exposure, <4 prior therapies, and Stage III cHL. Increased ORR in pts with recent prior CHPi could suggest a possible immunological interaction between Cami and prior CHPi, but it did not appear to increase autoimmune and neurologic TEAEs.